Contribute Try STAT+ Today

The Japanese government recently issued a so-called business improvement order to Celgene for failing to report more than 4,500 side effect cases for three of its drugs.

Specifically, the company did not tell the Pharmaceuticals and Medical Devices Agency about side effect reports relating to three cancer drugs — Revlimid, Pomalyst, and Lenadex — going back to 2010, when Revlimid was first approved in the country. Side effect reports are required to be filed within 15 days, or 30 days after patient reactions are noted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.